Rhinomed adds material boost to distribution

Scott Power


Rhinomed (RNO, Add, Price Target A$0.06) Following last month’s announcement that RNO signed with Symbion to distribute its innovative snoring product Mute, they have announced another large distribution partner in Australia in signing Sigma Pharmaceuticals, bringing a further 1,200 pharmacies to the table. This deal will effectively double the number of pharmacies stocking the product in Australia. With these signings, we are expecting a material pickup in 4Q revenues as sales of Mute compliment the growing base for the Turbines. We have not made any changes to our forecasts and maintain our Add recommendation and price target of A$0.06 Report attached

1 stock mentioned

Scott Power
Scott Power
Senior Analyst

Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media. I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these...


No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.


Sign In or Join Free to comment